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Abstract
PICALM (Phosphatidyl Inositol Clathrin Assembly Lymphoid Myeloid protein) is a ubiqui-
tously expressed protein that plays a role in clathrin-mediated endocytosis. PICALM also af-
fects the internalization and trafficking of SNAREs and modulates macroautophagy.
Chromosomal translocations that result in the fusion of PICALM to heterologous proteins
cause leukemias, and genome-wide association studies have linked PICALM Single Nucle-
otide Polymorphisms (SNPs) to Alzheimer’s disease. To obtain insight into the biological
role of PICALM, we performed gene expression studies of PICALM-deficient and PICALM-
expressing cells. Pathway analysis demonstrated that PICALM expression influences the
expression of genes that encode proteins involved in cholesterol biosynthesis and lipopro-
tein uptake. Gas Chromatography-Mass Spectrometry (GC-MS) studies indicated that loss
of PICALM increases cellular cholesterol pool size. Isotopic labeling studies revealed that
loss of PICALM alters increased net scavenging of cholesterol. Flow cytometry analyses
confirmed that internalization of the LDL receptor is enhanced in PICALM-deficient cells as
a result of higher levels of LDLR expression. These findings suggest that PICALM is re-
quired for cellular cholesterol homeostasis and point to a novel mechanism by which
PICALM alterations may contribute to disease.
Introduction
PICALM (Phosphatidyl Inositol Clathrin Assembly Lymphoid Myeloid protein) is a ubiqui-
tously expressed accessory adaptor protein that functions in Clathrin-Mediated Endocytosis
(CME) [1–3]. PICALM’s role in CME is mediated by its N-terminal ANTH domain that allows
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it to interact with Phosphatidylinositol 4,5-bisphosphate (PIP2) and associate with the plasma
membrane [4]. PICALM also binds to the clathrin heavy chain through a poorly defined cla-
thrin binding region in its C terminal region [5]. PICALM regulates the internalization and lo-
calization of specific cell surface proteins, such as the transferrin receptor (TfR) and the
epidermal growth factor receptor (EGFR). Loss of PICALM results in perturbed internalization
of TfR and EGFR, while PICALM overexpression has a dominant negative effect on the inter-
nalization of these receptors [2, 3, 5–7]. In addition, PICALM plays a key role in regulating
vesicle size, since PICALM deficiency results in enlarged and elongated vesicular formation
[2, 8, 9].
PICALM also regulates the internalization and localization of specific soluble NSF attach-
ment protein receptors (SNAREs), including VAMP2, VAMP3, and VAMP8 [8, 10–13]. These
SNAREs play important roles in vesicular trafficking, including the endosomal-lysosomal sys-
tem and macroautophagy [8, 10–13]. In the absence of PICALM, specific SNAREs are misloca-
lized and retained at the plasma membrane [12, 13]. We recently showed that PICALM
modulates macroautophagy as a result of its ability to regulate SNARE protein localization
[13]. The effect of PICALM on the cellular localization of SNAREs may impact other cellular
processes involving trafficking. Indeed, a recent study indicated a role for PICALM perturba-
tion in endosomal-lysosomal maturation affecting the intracellular trafficking of the cKIT re-
ceptor [14].
In addition to its role in endocytosis and SNARE localization in the cytoplasm, a fraction of
PICALM can also be found in the nucleus. PICALM contains a Nuclear Export Signal (NES)
that allows it to shuttle between the nucleus and the cytoplasm. The role of PICALM within
the nucleus is presently not known, although it can activate gene transcription in reporter as-
says [15].
PICALM alterations have been associated with several human diseases. The PICALM gene
was initially identified as a site of chromosomal translocation in a cell line derived from a lym-
phoma patient [16]. In the U937 cell line, PICALM is fused to AF10 as a result of a t(10;11)
chromosomal translocation that has since been described in a variety of hematologic malignan-
cies, including acute lymphoid and myeloid leukemias [17, 18]. We recently reported that
CALM contributes to the leukemogenic properties of CALM-AF10 as a result of its NES motif
[19, 20].
Several GenomeWide Association Studies (GWAS) have reported that specific single nucle-
otide polymorphisms (SNPs) within PICALM are associated with the development of late
onset Alzheimer’s Disease (LOAD) [21–24]. However, the mechanisms by which PICALM
contributes to the development of LOAD are unknown. Recent studies suggest that PICALM
may be involved in the production of toxic amyloid beta plaque formation [25]. Moreover,
PICALM is involved in macroautophagy and can affect Tau accumulation, both of which may
play essential roles in the development of LOAD [13].
To gain insight into the biology of PICALM, we performed microarray studies comparing
gene expression in Picalm knockout and PICALM-rescued cells. Pathway analysis suggested
that PICALM perturbation results in altered expression of genes in the cholesterol biosynthesis
pathway. Using quantitative PCR, we confirmed that PICALM overexpression and PICALM
loss results in elevated cholesterol biosynthesis pathway gene expression in multiple cell types.
Isotopic labeling studies demonstrated that reduction of PICALM levels results in both in-
creased cellular cholesterol levels and net scavenging rate. Collectively, these studies suggest
that PICALM plays a role in cellular cholesterol metabolism, highlighting a novel mechanism
by which alterations of PICALMmight contribute to disease.
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Materials and Methods
Ethics Statement
All in vivo and euthanasia procedures in this study were carried out in strict accordance with
the recommendations in the Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health. Adult mice were euthanized by CO2 exposure and fetuses were euthanized
by decapitation. The animal studies described here have been approved by the Duke University
Institutional Animal Care & Use Committee (IACUC) (Protocol# A021-13-01). All efforts
were made to minimize animal suffering.
Animal Welfare
The animal studies described here have been approved by the Duke University Institutional
Animal Care & Use Committee (IACUC) (Protocol# A021-13-01). Adult mice were eutha-
nized by CO2 exposure and fetuses were euthanized by decapitation. None of the experiments
performed involved animal suffering.
Cell Culture
HEK293 cells (ATCC, catalog # CRL-1573), MEFs [5] and retroviral packaging Plat-E cells (a
gift from T. Kitamura) [26] were maintained in DMEM (Gibco, Life Technologies, Grand Is-
land, NY, USA) supplemented with 10% fetal bovine serum (Gibco, Life Technologies), 1%
penicillin/streptomycin (Gibco, Life Technologies,). For lipid withdrawal experiments,
HEK293 cells were grown with 10% lipid deficient fetal calf serum (Sigma). CAD neuronal
cells (a gift from Dona Chikarashi (Duke University) in March 2012) [27, 28] were cultured in
DMEM/F12 (Gibco, Life Technologies) supplemented with 8% fetal bovine serum (FBS), peni-
cillin and streptomycin (Invitrogen, Carlsbad, CA, USA). HEK293 and Plat-E cells were trans-
fected by calcium chloride transfection [29]. HEK293 cells transfected with pRSMX vectors
were selected with puromycin (Sigma-Aldrich, St. Louis, MO, USA). MEFs and CAD cells were
infected by co-culture with filtered (0.45 uM filter) Plat-E supernatant in the presence of poly-
brene (Sigma-Aldrich) (2 μg/ml). Hematopoietic cell lines were generated by immortalizing
fetal liver cells harvested from E14 fit1 Picalmfit1-5R mouse embryos [5]. fit1 Picalmfit1-5R mice
have a mutation that codes for a non functional Picalm protein missing 82% of its amino acid
sequence ([30]), herein referred to as Picalm-/-. Fetal liver cells were retrovirally transduced
with MLL-ENL using the MSCV-IRES-eGFP vector [31] and serially replated in methylcellu-
lose culture to select immortalized hematopoietic progenitors as previously described [32].
Cells were maintained in liquid culture in RPMI medium supplemented with 10% FBS, gluta-
mine, penicillin and streptomycin (Invitrogen) with recombinant murine interleukin-3 and
stem cell factor (5 ng/ml and 50 ng/ml, respectively, Peprotech, Rocky Hill, NJ, USA). The dou-
bling times for cells used within the study were calculated using Eq 1. c(t) = cell number at time
t, t = time, c0 = cell number at time 0, k = exponential constant.
cðtÞ ¼ c0  e k^t Eq 1
DNA Constructs and Vectors
PICALM shRNA were expressed using the pRSMX retroviral vector (kindly provided by Louis
Staudt (NIH)) [33]. An shRNA directed against luciferase (5’ GTGGATTTCGAGTCGTCTT
TAAT-3’) was used as a negative control. Several shRNAs were used to knock down PICALM
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in human or murine cells: Picalm shRNA4 (5’-GCCTTAATGTTGACTTTGAAT-3’), Picalm
shRNA10 (5”- GAAATGGAACCACTAAGAA-3’), Picalm shRNA15 (5’-GAGCACAGATA
CAGTTTAT-3’). All shRNAs were cloned into HindIII and BglII sites. shRNA4 targets human
and mouse PICALM. shRNA10 targets human and mouse PICALM, however, results in no
knockown of human PICALM in HEK293 cells. shRNA15 targets human and mouse PICALM
but results in a very modest knockown of PICALM in mouse cells. Picalm knockout fetal liver
hematopoietic cells were rescued by retroviral transduction of human PICALM cDNA using
the MSCVneo retroviral vector [34]. Control cells were infected with the MSCVneo empty vec-
tor. Transduced cells were selected in G418 (Geneticin; Gibco, Life Technologies). Transfec-
tions into HEK293 cells were performed using calcium chloride transfection [29]. PICALM
overexpression experiments in HEK293 cells were performed using human PICALM cDNA
[5] subcloned into the bicistronic MSCV-IRES-eGFP (MIE) retroviral vector. The HEK293
control cells were transfected with the MSCV-IRES-eGFP (MIE) empty vector.
Antibodies and Reagents
The following reagents were used: rabbit anti-PICALM antibody (HPA019061, Sigma-Aldrich,
1:1000), mouse anti-actin antibody (AC-40, Sigma-Aldrich, 1:1000), rabbit anti-actin antibody
(A2066, Sigma-Aldrich, 1:1000), rabbit anti-SREBP2 antibody (ab28482, 1:1000, Abcam, Cam-
bridge, MA, USA,), IRDye680-conjugated donkey anti-rabbit antibody (926–68073, 1:5000,
LI-COR, Biosciences, Lincoln, NB, USA), PE-conjugated mouse anti-human LDLR antibody
(FAB2148P, 1:20, R&D Systems, Minneapolis, MN, USA), PE-conjugated mouse IgG Isotype
antibody (IC002P, 1:20, R&D Systems).
Western Blot Analysis
Cells were lysed in Laemmli buffer and lysates were resolved by SDS–PAGE electrophoresis
(using 7.5% acrylamide gels) and transferred to polyvinylidene difluoride membranes
(IPFL00010, Millipore, Billerica, MA, USA). Membranes were incubated with the appropriate
antibody overnight in Odyssey Blocking Buffer (Li-Cor) with 0.1% Tween-20. Membranes
were washed in TBS with 0.1% Tween-20. Secondary antibody incubation was performed in
Odyssey Blocking Buffer with 0.1% Tween-20 and 0.02% SDS for 30 min. Membranes were
washed and proteins were quantitated using an Odyssey Infrared fluorescence imaging system
(Li-Cor). All uncropped western blots are included as S5 Fig.
Microarray
Total RNA was isolated using Qiagen RNeasy Micro kit (Qiagen, Valencia, CA) according to
the manufacturer’s protocol and analyzed by Mouse Genome 430 2.0 Array (Affymetrix, Santa
Clara, CA, USA). Array data were then normalized by RMA for further analysis. To identify
differentially expressed genes, we applied the SAM 4.01 Excel Add-In that provides the esti-
mate of False Discovery Rate (FDR) for multiple testing. Using an FDR threshold of 12.3%, we
identified 343 probe sets, whose expression values were extracted, mean-centered [35] and
clustered by Cluster 3.0 and displayed by Treeview v1.6 as done [36] These selected genes were
then deposited into GATHER (gather.genome.duke.edu) [37] to determine the enrichment for
the Gene Ontology (GO) and KEGG (KEGG). Specifically, KEGG pathway analysis was used
in this study. All array analysis was conducted using log2 scale. The data discussed in this pub-
lication have been deposited in NCBI’s Gene Expression Omnibus and are accessible through
GEO Series accession number GSE64855.
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Quantitative RT-PCR Analysis
Total RNA was isolated fromMEFs using RNeasy Mini Kit (Qiagen). RNA was reverse tran-
scribed using iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA) according to the man-
ufacturer’s protocol. Real time quantitative PCR was performed using iQ Sybr-Green Mix
(Bio-Rad) according to the manufacturer’s protocol. Amplification data were collected using
the iQ5 Optical System (Bio-Rad). The expression levels of cholesterol biosynthesis genes were
normalized to beta 2-microglobulin (β2M) and then to empty vector or shRNA luciferase con-
trol cells by the ΔΔCT method. Primer pair sequences are provided in S1 Table and S2 Table.
Surface Expression and Internalization Assays
HEK293 cells growing exponentially were trypsinized with 0.05% Trypsin/EDTA (Invitrogen)
until approximately 30% of cells lifted off the plate. Trypsinization was stopped with serum-
containing ice cold media. Cells were washed with cold PBS and resuspended in HFN (Hanks
Balanced Salt Solution, FBS (2%), Sodium Azide (NaN3 0.02%) containing rat IgG (1 μg/ml)
for 20 min. Cells were then stained with anti-human LDLR-PE or mouse PE-conjugated IgG
Isotype control for 30 minutes on ice. Cells were washed twice with cold PBS and then directly
analyzed by flow cytometry (C6, Accuri, Ann Arbor, MI, USA) to measure LDL receptor sur-
face expression by quantification of mean fluorescence intensity. For internalization assays,
cells stained with antibodies and rinsed in PBS were divided into multiple tubes and incubated
at 25°C for indicated time points to induce internalization. Cells were incubated at 25°C rather
than 37°C to slow down LDL receptor internalization and improve accuracy of measurements.
Ice-cold acid wash buffer (0.5 M NaCl/0.2 M acetic acid) was added to halt receptor internali-
zation and strip residual LDL receptor from the cell surface. Cells were washed twice with cold
PBS and flow cytometry was used to measure the mean fluorescence intensity emitted by inter-
nalized LDL receptor molecules. The rate of LDL receptor internalization was calculated by di-
viding the LDL receptor internalized at each time point by the initial LDL receptor surface
expression.
Lipid Quantitation and 13C Tracer Analysis
HEK293 cells were cultured in glucose-free DMEM (Gibco, Life Technologies) supplemented
with 10% FBS, 1% pen/strep, and 25 mM glucose. Unlabeled cells were cultured in natural glu-
cose (Sigma-Aldrich), while labeled cells were cultured in a 1:1 molar ratio of natural to
U-13C6-glucose (110187-42-3, Cambridge Isotopes, Andover, MA, USA). To reach steady
state, cells were cultured in natural or label-containing medium for 6 d. The medium was
changed every 12 hours. Cells were grown at the same cell density and were maintained in a
subconfluent state by splitting every 48 hours. After 6 d (144 h) in natural or label-containing
medium, cells were collected, counted, washed, and frozen at -80°C. To obtain growth curves,
HEK293 shRNALuc and shRNA4 cells were grown in quadruplicate in the natural and label-
containing medium after splitting the cells on d4. Cells were counted 24 and 48 h after the ini-
tial plating in order to measure cellular growth rates. Doubling time was determined by fitting
cell counts at 24 h (120 h–d5) and 48 h (144 h–d6) to an exponential curve using Excel
(Microsoft).
Calibration curves were made using the GLC-96 fatty acid methyl ester (FAME) mix (Nu-
Chek Prep), methyl cis-vaccenate (Nu-Chek Prep), and cholesterol (Sigma). 4 μg of trinonade-
canoin (Nu-Chek Prep) and stigmastanol (Sigma-Aldrich) were added in 400 μL of toluene to
each sample as internal standards. 3 mL of methanol and 600 μL of 8% (w/v) HCl in methanol
were added to each sample before incubating at 45°C for 16 h. 2 mL of 0.04 M aqueous NaCl
was added to the reaction mix and FAMEs and free sterols were extracted twice using 2 mL of
PICALM and Cholesterol Metabolism
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n-hexane. The combined organic phases were dried under vacuum (EZ-2 Elite) and dissolved
in 300 μL n-hexane. One hundred μL of this solution was used directly for FAMEs analysis via
GC/MS. 150 μL of this solution was dried again under vacuum and dissolved in 25 μL of 1:1 (v/
v) pyridine and N,O-bis(trimethylsilyl) trifluoroacetamide with trimethylchlorosilane 99:1
(Sigma-Aldrich). The resulting trimethylsilyl derivatives were directly analyzed via GC/MS.
Data was collected on an Agilent 5975C MSD (Agilent Technologies, Santa Clara, CA,
USA) connected to an Agilent 7890A Gas Chromatograph (Agilent). FAMEs were analyzed on
the Agilent DB-WAX column (122–7032). Trimethylsilyl ether sterols were analyzed on a
ZB-MR-1 column (7HG-G016-11, Phenomenex, Torrance, CA, USA). GC/MS settings and
oven programs are available upon request. Ions monitored for each analyte are provided in S3
Table. Area under the curve (AUC) quantitation was conducted on ChemStation software
(Agilent). Absolute quantitation of fatty acids and cholesterol was achieved by first normalizing
the analyte AUC (sum of all collected isotopologues) to the internal standard AUC (M+0
only). This ratio was fit to the appropriate calibration curve and then normalized to cell num-
ber. The relative contributions of synthesis and scavenging were determined by fitting the iso-
topologue distributions at steady state (>5 divisions in label media) by modeling the
isotopologue distribution as described in [38, 39]. Note that for 16:1(n-7), the “scavenged” pop-
ulation includes scavenged 16:0 desaturated by stearoyl-CoA desaturase 1 (SCD1) inside the
cell. Net accumulation rates (R) were calculated using pool size (p), doubling time (d), and per-
cent contributions (c) using Eq 1. “Net rate” for a given metabolic parameter (e.g. synthesis) is
defined as the gross rate minus the rate of loss due to modification/breakdown/export.




Standard, two-tailed Student’s t-Test analysis was used for all statistical analysis. Values repre-
sent means ± SEM from at least three independent experiments. p values less than 0.05 were
considered statistically significant.
Results
PICALM Affects Cholesterol Biosynthesis Gene Expression
To better understand PICALM’s basic biological role, we established cell lines from Picalm-/-
mice [5, 30] to conduct microarray analyses. Immortalized fetal hematopoietic cells from E14
Picalm-/- embryos were retrovirally transduced to rescue PICALM expression. Control
Picalm-/- cells were transduced with an empty MSCVneo retroviral vector. Four biological rep-
licates of Picalm-/- cell lines, transduced with either PICALM or the empty vector, were used to
perform the microarray.
We used the GATHER (Gene Ontology Tool to Help Explain Relationships) gene ontology
tool to identify common pathways altered in Picalm knockout versus PICALM-rescued cell
lines [37]. This analysis revealed that nine GO terms involving lipid and cholesterol synthesis
(including GO:0006695, 0044255, 0016126, 0008610) were among the ten most significantly al-
tered pathways when comparing Picalm-/- and PICALM-rescued cells (Table 1). Expression
levels of multiple genes in the cholesterol biosynthesis pathway were elevated in PICALM-res-
cued compared with Picalm-/- cells (Fig 1A and 1B). These included Hmgcs (1.2 fold), Fdps
(1.3 fold), Fdft1 (1.3 fold), Cyp51 (1.2 fold) and Nsdhl (1.2 fold). Several genes involved in basic
cellular lipid metabolism were also increased in the presence of PICALM, including Dgat2 (1.5
PICALM and Cholesterol Metabolism
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fold),Mogat2 (2.4 fold), Slc27a4 (1.3 fold) and Pip5k1b (1.5 fold). Although some of the induc-
tions were modest, the concordant changes in numerous genes of the cholesterol biosynthesis
pathway strongly suggest that PICALM expression levels play a role in cholesterol metabolism.
Validation of the induction of cholesterol biosynthesis gene expression in PICALM-rescued
cells was performed by quantitative real time PCR (qPCR) (Fig 1C) and confirmed elevations
in cholesterol pathway gene expression. The top 40 up-regulated and down-regulated genes in
the microarray analysis are shown in S4 and S5 Tables, respectively.
The comparison of Picalm-/- with PICALM-rescued cells demonstrates that PICALM gene
dosage affects the expression of cholesterol biosynthesis genes. However, one caveat of this ex-
perimental approach is that the level of PICALM expression in rescued cells may exceed physi-
ological amounts; this could potentially squelch PICALM binding partners and have a
dominant negative effect that exceeds the effect resulting from mere loss of PICALM [3, 5]. To
examine this possibility, we compared wild type HEK293 cell, to cells transiently overexpres-
sing PICALM. We performed qPCR to compare the expression of cholesterol biosynthesis
genes in the empty vector control cells to that in the PICALM overexpressing cells. The results
show that PICALM overexpression induces an increase of cholesterol metabolism gene expres-
sion (Fig 1D) suggesting that PICALM overexpression perturbs cholesterol homeostasis. This
is consistent with studies showing that PICALM overexpression results in a dominant negative
effect on multiple processes, including clathrin mediated endocytosis ([3, 6], iron metabolism
[5] and macroautophagy (our unpublished data).
To elucidate and further validate the role of PICALM in cholesterol homeostasis, we
knocked down PICALM with shRNAs and compared cholesterol biosynthesis gene expression
in cells expressing a control shRNA. Using two separate shRNAs to knockdown PICALM in
HEK293 cells, we found a 20 to 50% increase in expression of cholesterol biosynthesis genes in
PICALM-deficient cells (Fig 2A).
To extend this observation to additional cell lines, we knocked down Picalm in murine em-
bryonic fibroblasts (MEFs). Similar to observations in HEK293 cells, we found that cholesterol
biosynthesis gene expression increased by 10–50% in Picalm-deficient MEFs (Fig 2B). We also
studied the effect of Picalm knockdown in the murine CAD (Cath-a-differentiated) neuronal
Table 1. Top Ten Biological Pathways Elevated in the Presence of PICALM*.
Number GO term neg ln
(p value)
Genes
1 GO:0006695 [8]: cholesterol biosynthesis 10.41 Cyp51, Fdft1, Hmgcs1, Nsdhl, Pmvk
2 GO:0044255 [5]: cellular lipid metabolism 10.41 Alox5ap, Cdipt, Cyp51, Dgat2, Fdft1, Fdps, Galc, Hmgcs1, Hsd11b1, Mogat2,
Nsdhl, Pip5k1b, Pmvk, Slc27a4
3 GO:0016126 [7]: sterol biosynthesis 10.41 Cyp51, Fdft1, Hmgcs1, Nsdhl, Pmvk
4 GO:0008610 [6]: lipid biosynthesis 10.41 Alox5ap, Cdipt, Cyp51, Dgat2, Fdft1, Fdps, Hmgcs1, Mogat2, Nsdhl, Pmvk
5 GO:0006629 [5]: lipid metabolism 10.41 Alox5ap, Cdipt, Cyp51, Dgat2, Fdft1, Fdps, Galc, Hmgcs1, Hsd11b1, Mogat2,
Nsdhl, Pip5k1b, Plcb2, Pmvk, Slc27a4
6 GO:0008203 [7]: cholesterol metabolism 9.16 Cyp51, Fdft1, Hmgcs1, Nsdhl, Pmvk
7 GO:0016125 [6]: sterol metabolism 8.8 Cyp51, Fdft1, Hmgcs1, Nsdhl, Pmvk
8 GO:0006066 [5]: alcohol metabolism 8.62 Cyp51, Fdft1, Gpd2, Hk1, Hmgcs1, Nsdhl, Pmm1, Pmvk
9 GO:0006694 [7]: steroid biosynthesis 8.16 Cyp51, Fdft1, Hmgcs1, Nsdhl, Pmvk
10 GO:0007186 [6]: G-protein coupled receptor
protein signaling pathway
7.85 Arrb2, Ccr5, Ltb4r1, Mrgpra2
* Genes selected for further study are indicated in boldface.
doi:10.1371/journal.pone.0129776.t001
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cell line, a central nervous system catecholaminergic cell line established from a mouse brain
tumor [27, 28]. Reduction of Picalm expression in CAD neuronal cells resulted in a 20–50% in-
crease in cholesterol biosynthesis gene expression (Fig 2C).
We found that growing cells under lipid-deprived conditions (5 and 24 hours) increases the
expression of cholesterol biosynthesis genes. In the absence of lipids, the levels of expression of
these genes are not significantly different between PICALM-deficient and control HEK293
cells (S1 Fig). These results suggest that the PICALM-deficient cells display a lesser response to
lipid starvation, possibly because they are already sensing lipid deprivation under normal
growth conditions.
Finally, to further examine the effect of PICALM perturbation on cholesterol homeostasis,
we studied its effect on expression of SREBP2, a key regulator of cholesterol metabolism gene
expression [40]. SREBP2 is present in a precursor (120 kDa) inactive form, and a mature (65
kDa) active form that activates the transcription of cholesterol biosynthesis genes. To comple-
ment the gene expression analysis, we found that PICALM loss is associated with a modest
elevation of the mature 65 kDa SREBP2 form in HEK293 cells (Fig 2D). Similar results were
seen with shRNA15 (S2A Fig). Of note, we have observed that changes in levels of SREBP2
Fig 1. Microarray analysis identifies altered cholesterol biosynthesis gene expression in Picalm-knockout and PICALM-rescued cells. (A)
Heatmap comparing microarray gene expression profile of four Picalm-knockout (left panels) and four PICALM-rescued (right panels) murine hematopoietic
cell lines. Red indicates genes that are upregulated, green indicates those that are downregulated. Genes of the cholesterol pathway are indicated to the
right of the heatmap. (B) Simplified diagram of cholesterol biosynthesis pathway indicating enzymes that are overexpressed in PICALM-rescued cells by the
microarray study. (C) Validation of microarray results by qPCR in hematopoietic fetal liver cells (upper panel). Expression is normalized to Picalm-knockout
cells. Data represent the mean of 3 independent experiments. *p<0.05. Immunoblot (lower panel) shows PICALM and actin protein levels in representative
Picalm-knockout and PICALM-rescued hematopoietic cells. Doubling times of fetal liver cells (14 hours) and HEK293 cells (11 hours) were calculated using
Eq 1 in Materials and Methods. (D) Cholesterol biosynthesis gene expression was measured in HEK293 cells transiently transfected with a control retrovirus
(Empty Vector) or PICALM expressing retroviral vector (+PICALM). Data represent the mean of 3 independent experiments. Results are shown normalized
to control cells. *p<0.05. Immunoblot in right panel shows levels of PICALM and actin proteins.
doi:10.1371/journal.pone.0129776.g001
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mature/active form seen by immunoblotting are not striking; even upon growing HEK293 cells
in lipid deficient conditions for 24 hours–conditions that would be expected to dramatically in-
crease SREBP2 levels–we only see a 45% increase in the mature SREBP2 product (S2B Fig).
Fig 2. PICALM knockdown leads to increased cholesterol biosynthesis gene expression in multiple cell types. Cholesterol biosynthesis gene
expression asessed by qPCR in cells expressing a luciferase control shRNA (shRNALuc) or various PICALM shRNAs (shRNA4, 10 or 15). Analysis was
done in HEK293 cells (A), MEFs (B) and CAD Neuronal cells (C). Expression levels are normalized to those in shRNA control cells. Results shown are mean
of three or more independent experiments. *p<0.05. Expression analysis of PICALM and actin in the various cell lines are shown by immunoblot in lower
panels. Doubling times of cells were calculated using Eq 1 in Materials and Methods, HEK293, 11 hours, MEFs 14 hours, and CAD cells, 18 hours. (D) Levels
of SREBP2 precursor (120 kDa) and mature form (70 kDa) measured by immunoblot in HEK293 cells expressing shRNA4 or shRNALuc control. Triplicate
cell lysates were analyzed. Lower panel demonstrates quantitation of SREBP2 precursor and mature forms normalized to actin, with values shown relative to
levels in shRNA control cells. *p<0.05.
doi:10.1371/journal.pone.0129776.g002
PICALM and Cholesterol Metabolism
PLOSONE | DOI:10.1371/journal.pone.0129776 June 15, 2015 9 / 20
The gene expression analysis along with a subtle elevation of SREBP2, indicate that cholesterol
homeostasis is altered when PICALM expression is perturbed.
PICALM Loss Enhances Cellular Cholesterol and LDL Receptor
Internalization
Our studies demonstrate that loss of PICALM results in elevated expression of genes that are
involved in both cholesterol biosynthesis and lipoprotein uptake. We reasoned that this gene
signature might be the result of decreased cellular cholesterol content leading to a compensato-
ry increase in cholesterol biosynthesis or increased cholesterol scavenging. To address this pos-
sibility, total cellular cholesterol was analyzed by Gas Chromatography-Mass Spectrometry
(GC-MS). Unexpectedly, these studies revealed that knockdown of PICALM in HEK293 cells
results in increased total cellular cholesterol levels (Fig 3A). We therefore performed 13C tracer
analysis to determine if the relative contributions of synthesis and scavenging to the cellular
cholesterol pool had changed. PICALM knockdown and control cells were cultured to steady
state in complete media containing a 1:1 molar ratio of U-13C6 glucose and natural glucose
[39] and total cellular cholesterol was extracted, derivatized and measured by GC-MS. The
Fig 3. Total cholesterol levels, net scavenging, and net total accumulation are elevated in PICALM knockdown cells. (A) Total cellular cholesterol
levels were measured in HEK293 cells expressing a control (luciferase) shRNA or PICALM shRNA (shRNA4). All results were normalized to total cell
number. n = 4; *p<0.05. (B) The relative contribution of synthesis and scavenging to cellular cholesterol was calculated at steady state by modeling
isotopologue distribution of cholesterol in indicated cells cultured in 1:1 molar ratio of natural to U-13C6-glucose (n = 4 in each experimental group). (C) Net
rates of cholesterol synthesis, scavenging and total accumulation were calculated using cholesterol pool size, relative contribution of synthesis and
scavenging to cholesterol pool, and doubling time of cells as described in Materials and Methods. n = 4 in each experimental group; *p<0.05.
doi:10.1371/journal.pone.0129776.g003
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isotope distribution for cholesterol was assessed, and relative contribution of synthesis versus
scavenging was determined by modeling the isotopologue distribution (see Methods for de-
tailed protocol) [39]. We observed that PICALM knockdown cells had a higher percent abun-
dance of unlabeled cholesterol, suggesting an increased relative reliance on scavenging
compared to synthesis (Fig 3B). To better understand the relative importance of scavenging
and synthesis, we calculated the net rates of accumulation (hereafter referred to as “net rates”)
for synthesis and scavenging, which represent the gross rate minus losses due to modification,
breakdown, or export (see Methods). PICALM knockdown did not appear to affect the net rate
of cholesterol biosynthesis (Fig 3C). In contrast, we found that PICALM knockdown results in
significantly elevated net rates of cholesterol scavenging and total cholesterol accumulation
(Fig 3C). Several species of fatty acids also showed increased cellular pool sizes and increased
net scavenging rates in the absence of PICALM (S3 and S4 Figs). Taken together, these results
indicate that reduced PICALM expression is associated with increased cellular cholesterol
content and a relative increase in the contribution of lipoprotein scavenging to cholesterol
homeostasis.
The LDL receptor is one of the principal routes by which cholesterol enters into the cell; its
internalization is dependent on clathrin-mediated endocytosis (CME) [41–43]. Since PICALM
plays a well-established role in CME, we sought to determine how reduced PICALM expression
affects LDL receptor internalization. As shown in Fig 4A, knockdown of PICALM in HEK293
cells is associated with a significant increase in LDL receptor expression at the cell surface. This
increase in surface LDL receptor protein correlates with the increase in LDL receptor mRNA
transcript seen by qPCR (Fig 2A and 2B). Similar results were seen with a separate shRNA
(shRNA15). Endocytosis assays showed an increase in the net amount of LDL receptor inter-
nalized in PICALM knockdown cells (Fig 4B). The efficiency of LDL receptor internalization,
measured as the ratio of LDL receptor internalized to the amount initially present at the cell
surface, was not altered in PICALM knockdown cells (Fig 4C).
Discussion
Cholesterol is essential for cell survival. The majority of cellular cholesterol is found within the
plasma membrane, where it regulates membrane rigidity and permeability, and modulates spe-
cific aspects of cell signaling [42–47]. Cholesterol homeostasis ensures a balance between
internalization of extracellular cholesterol and endogenous synthesis. Cells scavenge cholester-
ol when complexed with lipoproteins. This internalization occurs predominantly through
clathrin-mediated endocytosis (CME) of LDL, via a variety of receptors belonging to the LDL
receptor family [41–43]. Once cholesterol is internalized, it is trafficked through the endoso-
mal-lysosomal system, and released from the lysosome to the cytoplasm and various cellular
compartments within the cell. If cholesterol internalization is blocked, or if there are defects in
cholesterol trafficking, SREBP2, the main regulator of cholesterol biosynthesis gene expression,
can activate expression of cholesterol biosynthesis genes to restore cellular cholesterol levels
[41–43]. Importantly, maintaining cellular cholesterol homeostasis is essential, since defects
can lead to a wide range of diseases such as cancer, atherosclerosis, and neurodegenerative dis-
ease [41, 48, 49].
We performed a microarray analysis of Picalm-deficient and PICALM-rescued murine he-
matopoietic cells and showed that PICALM perturbation appears to modulate cellular choles-
terol biosynthesis gene expression. However, in this overexpression model, PICALM levels in
rescued cells may have been supraphysiologic. Cells that express “wild type” levels of PICALM
exhibit baseline levels of cholesterol biosynthesis genes. It is straightforward to understand
how reduced PICALM levels could perturb expression by impairing normal PICALM activity.
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Previous studies have shown that PICALM overexpression can result in PICALM having a
dominant negative effect on multiple cellular processes [3, 5]. Thus, both PICALM overexpres-
sion and PICALM reduction can result in a similar phenotype. To show that elevated PICALM
expression levels alters cellular cholesterol homeostasis, we overexpressed PICALM in
HEK293 cells. This resulted in elevated cholesterol metabolism gene expression, indicating that
PICALM overexpression may exert a dominant negative effect on cholesterol homeostasis. To
demonstrate that physiological levels of PICALM regulate cholesterol homeostasis, we knocked
down PICALM expression using shRNAs. The results of Fig 2 show that PICALM deficiency
leads to elevated expression of cholesterol biosynthesis genes.
Multiple studies indicate that proteins involved in CME and endosomal-lysosomal traffick-
ing can play key roles in maintaining normal cellular cholesterol homeostasis [50–55]. Given
PICALM’s well-established contribution to CME and its possible role in cellular trafficking, [2,
14, 56] we explored how PICALM perturbation might modulate cellular cholesterol metabo-
lism. To this end, we used 13C tracer analysis [39]. Our studies demonstrate that PICALM
Fig 4. PICALM shRNA knockdown increases LDL receptor surface expression and internalization. (A) LDL receptor surface expression measured by
flow cytometry in HEK293 cells expressing a luciferase shRNA (shRNALuc) control or PICALM shRNA (shRNA4). Expression levels are normalized to
shRNALuc control cells. Results represent the mean of at least three independent experiments. *p<0.05. Endocytosis assays show the net amount of LDL
receptor internalized (B) and the fraction of internalized LDL receptor relative to the initial amount of surface LDL receptor (C), as a function of incubation time
at 25°C in shRNALuc control or PICALM shRNA (shRNA4) cells. Each data point is the mean of three independent experiments. MFI = mean
fluorescence intensity.
doi:10.1371/journal.pone.0129776.g004
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knockdown results in both elevated net cholesterol scavenging and increased total cellular
cholesterol levels (Fig 3). Furthermore, several species of fatty acids also showed increased cellu-
lar pool sizes and increased net scavenging rates in the absence of PICALM (S3 and S4 Figs), in-
dicating that PICALMmay play a broader role in cellular lipid homeostasis. Interestingly, loss of
PICALM did not result in a significant change in net cholesterol synthetic rate. This result could
be explained by a variety of factors. It is known that increased cellular cholesterol can inhibit flux
through the mevalonate cholesterol biosynthetic pathway via posttranscriptional mechanisms,
such as degradation of HMG-CoA reductase [57] and squalene monooxygenase [58]. Alterna-
tively, it is also possible that increased cholesterol levels result in heightened cholesterol efflux
[59] in PICALM-deficient cells. In this scenario, heightened cholesterol efflux could result in an
underestimation of the magnitude of change in gross synthetic rate between PICALM-sufficient
and-deficient cells. Nevertheless, the concomitant increase of net cholesterol import, with activa-
tion of cholesterol biosynthesis pathway gene expression, suggests that cholesterol homeostasis is
profoundly perturbed in PICALM-deficient cells [60, 61].
Our studies further demonstrate that reduced PICALM results in elevated LDL receptor
surface expression and internalization (Fig 4). However, PICALM reduction does not appear
to affect the efficiency of LDL receptor internalization (Fig 4). These results suggest that
PICALM does not play an essential role in the internalization of the LDL receptor from the cell
surface, but rather that PICALMmay be required for the proper intracellular trafficking of in-
ternalized cholesterol. We propose that the elevated levels of LDL receptor surface expression
and internalization are a result of increased expression of the LDL receptor, caused by pertur-
bation of cholesterol homeostasis.
Several reports indicate that PICALM affects cellular trafficking through the endosomal-ly-
sosomal system [13, 14, 56]. PICALMmodulates the localization and activity of SNARE pro-
teins such as VAMP3 and VAMP8, both of which are important for endosomal-lysosomal
function and macroautophagy [62, 63]. Our previous studies have shown that PICALM’s abili-
ty to modulate the localization of VAMP3 and VAMP8, results in perturbed macroautophagy.
[13]. Intriguingly, these SNARE proteins have been shown to be mislocalized in Niemann-Pick
Type C (NPC) disease, which is characterized by perturbed endosomal-lyososomal trafficking
of cholesterol and altered cholesterol homeostasis [60, 64–66]. It has also been demonstrated
that macroautophagy is altered in NPC disease [63–65]. Collectively, this suggests that an alter-
ation in PICALM levels can lead to altered cellular cholesterol homeostasis by mislocalization
of VAMP3 and VAMP8 SNARE proteins, which contribute to both improper cholesterol traf-
ficking and macroautophagy [64, 67]. Perturbation of both macroautophagy and cholesterol
trafficking may contribute to the elevated cholesterol biosynthesis gene expression, LDL recep-
tor surface expression and internalization, and cholesterol uptake, as the cells are unable to
sense cellular cholesterol in the absence of PICALM. Deciphering the precise mechanism is be-
yond the scope of this study.
Our observations suggest that PICALM plays a regulatory role in maintaining cellular cho-
lesterol homeostasis. In addition, they support a novel mechanism by which PICALMmight
contribute to disease. Multiple independent GenomeWide Association Studies (GWAS) indi-
cate that PICALM SNPs play a role in the development of late-onset Alzheimer’s Disease (AD)
[21–24]. However, how these SNPs affect PICALM expression levels or function is poorly un-
derstood; some studies suggest that PICALM is overexpressed, while others indicate that a re-
duction in PICALM activity can play a pathogenic role in AD [68–71]. Alterations in PICALM
levels may modulate amyloid beta protein formation and Tau accumulation [13, 25]. The pres-
ent work suggests that the ability of PICALM to modulate cholesterol biology might be an ad-
ditional mechanism by which PICALM contributes to AD. This is consistent with a number of
PICALM and Cholesterol Metabolism
PLOSONE | DOI:10.1371/journal.pone.0129776 June 15, 2015 13 / 20
studies that have linked perturbed cholesterol metabolism to late-onset AD, as well as other
neurodegenerative diseases [72–79].
The expression of APOE, a key lipoprotein and carrier of cholesterol in the brain, has been
shown to be a highly significant risk factor in the development of late-onset AD [23, 80]. Meta-
analysis studies suggest that PICALM and APOEε4 may synergistically interact to help pro-
mote the development of AD [22, 81]. However, the manner by which APOE and PICALM
might act together to promote the development of AD are not understood. Our work suggests
that these risk factors may cooperate to promote the development of AD through the modula-
tion of cellular cholesterol metabolism.
In summary, the studies presented here provide evidence to suggest that PICALMmodu-
lates cellular cholesterol metabolism. Loss of PICALM activates cellular cholesterol biosynthe-
sis gene expression, increases LDL receptor surface expression and internalization, enhances
cholesterol uptake, and increases total cellular cholesterol. This phenotype suggests that choles-
terol sensing is abnormal when PICALM activity is perturbed. This novel role of PICALM in
cellular cholesterol homeostasis has implications in understanding how PICALMmight con-
tribute to disease.
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S1 Fig. shRNA knockdown of PICALM does not lead to altered cholesterol biosynthesis
gene expression, when compared to control cells, in lipid deficient conditions. Cholesterol
biosynthesis gene expression was measured by qPCR in cells expressing a control (luciferase)
shRNA or PICALM shRNAs (shRNA4). Analysis was performed in HEK293 cells grown in
normal conditions (10% serum–fetal bovine serum, FBS) (n = 6, n = 5 for Hmgcr) or 10% lipid
deficient serum (LPDS) for 5 hours (n = 3) or 24 hours (n = 3). Expression levels were normal-
ized to those of shRNA control cells in normal conditions. p<0.05
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S2 Fig. shRNA knockdown of PICALM results in modest elevation of the mature form of
SREBP2. (A) The precursor (120 kDa) and SREBP2 mature form (70 kDa) were measured by
immunoblot in HEK293 cells expressing shRNA15 or a control shRNA. A higher exposure of
the precursor form is shown to facilitate its visualization. Triplicate cell lysates were analyzed
in 3 separate experiments. Quantitation of SREBP2 precursor and mature forms were normal-
ized to actin, with values shown relative to levels in shRNA control cells. The uncropped
western blot is provided in S5 Fig. (B) The precursor (120 kDa) and mature form of SREBP2
(70 kDa) were measured by immunoblot in HEK293 cells grown in normal, 10% serum (fetal
bovine serum, FBS) or 10% Lipid deficient serum (LPDS) for 24 hours, n = 3 p<0.05.
(TIFF)
S3 Fig. Total Fatty acid levels are maintained or elevated in the absence of PICALM. Total
fatty acid levels were measured in HEK293 cells expressing a luciferase shRNA (shRNALuc)
control or PICALM shRNA (shRNA4), in media containing a 1:1 molar ratio of natural to
U-13C6-glucose. Fatty acid abbreviations are indicated in S3 Table. All results were normalized
to cell number. n = 4 in each experimental group p<0.05.
(TIFF)
S4 Fig. Net fatty acid scavenging, synthesis, and total accumulation are maintained or ele-
vated in the absence of PICALM. Net rates of fatty acid synthesis, scavenging and accumula-
tion were calculated for shRNA luciferase (shRNALuc) control and PICALM knockdown
(shRNA4) HEK293 cells in media containing a 1:1 molar ratio of natural to U-13C6-glucose
using cellular pool size, relative contribution of synthesis and scavenging, and doubling time of
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